NCT05839600终止1 期
An Open-label, Phase I Dose Escalation and Expansion Trial to Investigate Safety and Efficacy of BI 1821736 in Patients With Advanced Solid Tumors
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 10
- 试验地点
- 15
- 主要终点
- Occurrence of Dose Limiting Toxicities (DLTs) in the Maximum Tolerated Dose (MTD) evaluation period
研究概览
简要总结
This study is open to adults with advanced solid tumours. People with solid tumours for whom previous treatment was not successful or no treatment exists can take part.
The purpose of this study is to find the highest dose of a medicine called BI 1821736 that people with advanced solid tumours can tolerate. BI 1821736 is a type of immunotherapy. It is a special virus that kills cancer cells and helps the immune system fight cancer. In this study, BI 1821736 is given to humans for the first time.
Participants receive BI 1821736 as an infusion into a vein about every 3 weeks for up to 3 months. Study doctors regularly check the participants' health and monitor the tumours. The doctors also take note of any unwanted effects that could have been caused by BI 1821736.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed diagnosis of malignant tumor.
- •Advanced, unresectable and/or metastatic or relapsed/refractory solid tumors.
- •Has failed conventional treatment or for whom no therapy of proven efficacy exists or who is not eligible for established treatment options. Patient must have exhausted available treatment options known to prolong survival for their disease.
- •Has at least one tumoral lesion which is amenable to biopsy.
- •Signed and dated, written informed consent form (ICF) in accordance with ICH-GCP and local legislation obtained prior to any trial-specific procedures, sampling, or analyses that are not part of normal standard of practice care.
- •Eastern Cooperative Oncology Group score of 0 or
- •Adequate organ function or bone marrow reserve defined as demonstrated at screening by the following laboratory values:
- •Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (≥ 1.5 x 10^3/μL)(≥ 1500/mm^3); haemoglobin ≥ 90 g/L (≥ 9.0 g/dL)(≥ 5.6 mmol/L); platelets ≥ 100 x 10^9/L (≥ 100 x 10^3/μL)(≥ 100 x 10^3/mm^3) without the use of haematopoietic growth factors within 4 weeks of start of trial medication.
- •Creatinine ≤ 1.5 times the upper limit of normal (ULN).
- •Total bilirubin ≤ 1.5 times the ULN, except for patients with Gilbert's syndrome: total bilirubin ≤ 3 times ULN or direct bilirubin ≤ 1.5 times ULN.
- •Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 times ULN if no demonstrable liver metastases, or otherwise ≤ 5 x ULN if transaminase elevation is attributable to liver metastases.
- •Partial thromboplastin (PT) / activated partial thromboplastin time (aPTT) <1.5 times ULN unless on a stable dose of an anticoagulant.
- •All toxicities related to previous anti-cancer therapies have resolved to ≤ Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 prior to trial treatment administration (except for alopecia and peripheral neuropathy which must be ≤ CTCAE Grade 2 and amenorrhea/menstrual disorders which can be any grade).
- •Further inclusion criteria apply
排除标准
- •Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to start of study treatment.
- •Previous treatment with Vesicular Stomatitis Virus (VSV)-based agents.
- •Patients with brain metastases unless they have completed brain radiotherapy and are asymptomatic.
- •Radiotherapy within 4 weeks prior to the start of study treatment, except in case of a brief course of palliative radiotherapy (e.g. for analgesic purpose or for lytic lesions at risk of fracture) which can then be completed within two weeks prior to start of study treatment.
- •Note: No radiation must have been given to any lesions planned to be biopsied within 6 months of start of treatment.
- •Prior (within 3 weeks of first dose) or concomitant use of systemic corticosteroids (>10 mg daily prednisone or equivalent).
- •Prior (within 3 weeks of first dose or less than 5 half-lives) or concomitant use of a medication or a condition considered a high risk for complications from biopsy as per the Investigator's judgement.
- •Prior (within 3 weeks of first dose or less than 5 half-lives) or concomitant use of interferon, immunotherapy agents, or tamoxifen.
- •Active infection requiring systemic therapy (antibacterial, antiviral, antiparasitic or antifungal therapy) at the start of treatment in the trial.
- •Further exclusion criteria apply
结局指标
主要结局
Occurrence of Dose Limiting Toxicities (DLTs) in the Maximum Tolerated Dose (MTD) evaluation period
时间窗: up to 21 days
次要结局
- Occurrence of Adverse Events (AEs) during the on-treatment period(up to 3 months)
- Occurrence of DLTs during the on-treatment period(up to 3 months)
研究者
研究点 (15)
Loading locations...
相似试验
进行中（未招募）
1 期
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are ToleratedSolid TumorsNCT05327946Boehringer Ingelheim42
进行中（未招募）
1 期
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck CancerNCT04958239Boehringer Ingelheim151
终止
1 期
Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid TumorsTumorsNCT00105170Biogen13
招募中
1 期
A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)Solid TumorsNCT05471856Boehringer Ingelheim66
进行中（未招募）
1 期
Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid TumorsAdvanced Solid TumorsNCT05537987InnoCare Pharma Inc.30